Reddy M M, Winger E E, Hargrove D, McHugh T, McKinley G F, Grieco M H
AIDS Clinical Trials Unit, St. Luke's-Roosevelt Hospital Center, New York, New York 10019.
J Clin Lab Anal. 1992;6(3):125-9. doi: 10.1002/jcla.1860060305.
Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured by a highly sensitive HIV p24 antigen-capture enzyme-linked immunosorbent assay (ELISA) in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) otherwise negative for HIV p24 antigen measured by a commercial antigen-capture ELISA. The assays were performed at baseline and at several intervals during treatment with either zidovudine (ZDV) or dideoxyinosine (ddl). To further enhance the rate of antigen detection, serum was pretreated with hydrochloric acid to denature antibody in immune complexes. Utilizing this assay system, we monitored these patients for drug efficacy. HIV p24 antigen levels obtained by using this sensitive assay decreased in 3 of 8 patients receiving ZDV during 8 weeks of ZDV treatment. Similarly, ddl administration was associated with a decrease of HIV p24 antigen levels in 3 of 5 patients. Thus, the use of the highly sensitive HIV p24 antigen assay permitted the monitoring of surrogate HIV p24 antigen as a measure of efficacy of anti-retroviral therapy in all of these patients who were otherwise HIV p24 antigen-negative at the onset of anti-retroviral therapy.
采用高灵敏度的HIV p24抗原捕获酶联免疫吸附测定法（ELISA），对获得性免疫缺陷综合征（AIDS）患者及艾滋病相关综合征（ARC）患者的循环人类免疫缺陷病毒（HIV）p24抗原水平进行检测，这些患者通过商业抗原捕获ELISA法检测HIV p24抗原结果为阴性。检测在基线期以及接受齐多夫定（ZDV）或双脱氧肌苷（ddI）治疗期间的多个时间点进行。为进一步提高抗原检测率，血清用盐酸预处理，以使免疫复合物中的抗体变性。利用该检测系统，我们对这些患者的药物疗效进行了监测。在接受ZDV治疗的8周内，8例接受ZDV治疗的患者中有3例，通过这种灵敏检测法测得的HIV p24抗原水平下降。同样，5例接受ddI治疗的患者中有3例，HIV p24抗原水平下降。因此，对于所有在抗逆转录病毒治疗开始时HIV p24抗原呈阴性的患者，使用高灵敏度HIV p24抗原检测法能够监测替代HIV p24抗原，以此作为抗逆转录病毒治疗疗效的一项指标。
